[go: up one dir, main page]

ECSP13013050A - Formulación para anticuerpo anti- 4 7 - Google Patents

Formulación para anticuerpo anti- 4 7

Info

Publication number
ECSP13013050A
ECSP13013050A ECSP13013050A ECSP13013050A EC SP13013050 A ECSP13013050 A EC SP13013050A EC SP13013050 A ECSP13013050 A EC SP13013050A EC SP13013050 A ECSP13013050 A EC SP13013050A
Authority
EC
Ecuador
Prior art keywords
antibody
formulation
antibody anti
formulations
degradation
Prior art date
Application number
Other languages
English (en)
Inventor
Jason Brown
Vaithianathan Palaniappan
Nobel T Truong
Csanad M Varga
Irving H Fox
Catherine Scholz
Willow Diluzio
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP13013050A publication Critical patent/ECSP13013050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)

Abstract

Se describen formulaciones de anticuerpo que comprenden una mezcla de un azúcar no reductor, anticuerpo anti- 4 7 y al menos un aminoácido. Las formulaciones descritas tienen una estabilidad mejorada, una formación de agregados reducida y pueden retrasar la degradación del anticuerpo anti- 4 7 en las mismas o presentar cualquier combinación de las mismas.
ECSP13013050 2011-05-02 2013-11-26 Formulación para anticuerpo anti- 4 7 ECSP13013050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
ECSP13013050A true ECSP13013050A (es) 2014-01-31

Family

ID=46085207

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP13013050 ECSP13013050A (es) 2011-05-02 2013-11-26 Formulación para anticuerpo anti- 4 7
ECSENADI202234515A ECSP22034515A (es) 2011-05-02 2022-04-29 FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECSENADI202234515A ECSP22034515A (es) 2011-05-02 2022-04-29 FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7

Country Status (42)

Country Link
US (16) US20120282249A1 (es)
EP (4) EP3329965B1 (es)
JP (7) JP6190360B2 (es)
KR (8) KR20250094743A (es)
CN (4) CN108079291B (es)
AR (1) AR086237A1 (es)
AU (7) AU2012250873B2 (es)
BR (1) BR112013028424A2 (es)
CA (2) CA2834867C (es)
CL (2) CL2013003146A1 (es)
CO (1) CO6801647A2 (es)
CR (1) CR20130677A (es)
CY (1) CY1119435T1 (es)
DK (2) DK3329965T3 (es)
DO (1) DOP2013000253A (es)
EA (1) EA032729B1 (es)
EC (2) ECSP13013050A (es)
ES (2) ES3016382T3 (es)
FI (1) FI3329965T3 (es)
GE (1) GEP201706734B (es)
HK (1) HK1249466A1 (es)
HR (2) HRP20250472T1 (es)
HU (2) HUE036663T2 (es)
IL (5) IL296847A (es)
LT (2) LT3329965T (es)
MA (1) MA35136B1 (es)
ME (1) ME02859B (es)
MX (4) MX348814B (es)
MY (2) MY183471A (es)
PE (2) PE20141175A1 (es)
PH (3) PH12018500030B1 (es)
PL (2) PL3329965T3 (es)
PT (2) PT3329965T (es)
RS (2) RS66809B1 (es)
SG (1) SG194652A1 (es)
SI (2) SI2704798T1 (es)
SM (2) SMT201700508T1 (es)
TW (3) TWI664978B (es)
UA (2) UA116189C2 (es)
UY (1) UY34053A (es)
WO (1) WO2012151248A2 (es)
ZA (3) ZA201308069B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3311834A1 (en) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
JP6382935B2 (ja) * 2013-03-15 2018-08-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 抗ｅｇｆｒ抗体薬物複合体製剤
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
MX384635B (es) * 2014-04-16 2025-03-14 Biosimilars Newco Ltd Formulaciones de proteína estables que comprenden un exceso molar de sorbitol.
WO2016057424A1 (en) * 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
AU2016306320B2 (en) * 2015-08-11 2022-04-14 Osaka University Antibody
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
EP3430053A1 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
MA44408A (fr) * 2016-03-14 2019-01-23 Millennium Pharm Inc Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
EP3468597A1 (en) * 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
CN118873480A (zh) 2016-10-07 2024-11-01 瑞泽恩制药公司 室温稳定的冻干蛋白质
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
LT3558391T (lt) * 2016-12-23 2022-07-11 Immunogen, Inc. Imunokonjugatai, kurių taikinys yra adam9, ir jų naudojimo būdai
KR20190141148A (ko) * 2017-04-28 2019-12-23 밀레니엄 파머슈티컬스 인코퍼레이티드 소아 장애를 치료하는 방법
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US20200087401A1 (en) * 2017-05-26 2020-03-19 Millennium Pharmaceuticals, Inc. Methods for the treatment of chronic pouchitis
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
KR20200069316A (ko) 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP2021521171A (ja) * 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 治療用抗体の安定な製剤
BR112020020741A2 (pt) * 2018-04-10 2021-01-19 Dr. Reddy's Laboratories Limited Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
WO2019198100A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Antibody formulation
WO2019230919A1 (ja) 2018-05-31 2019-12-05 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
PH12021551916A1 (en) 2019-02-18 2022-05-23 Lilly Co Eli Therapeutic antibody formulation.
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
PL439809A1 (pl) * 2019-06-10 2022-12-05 Takeda Pharmaceutical Company Limited Metody wytwarzania przeciwciała anty-alfa4beta7
CN118909120A (zh) * 2019-06-10 2024-11-08 武田药品工业株式会社 抗体纯化方法及其组合物
KR20220019725A (ko) * 2019-06-10 2022-02-17 다케다 야쿠힌 고교 가부시키가이샤 항체를 생성하기 위한 세포 배양 방법 및 조성물
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
TWI878456B (zh) 2020-02-18 2025-04-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
AR122983A1 (es) 2020-07-16 2022-10-19 Abbvie Inc ANTICUERPOS ANTI-a4b7
US20240100158A1 (en) * 2021-01-20 2024-03-28 Dr. Reddy’S Laboratories Limited Freeze dried antibody formulations and methods thereof
EP4333878A4 (en) * 2021-05-07 2025-03-19 Dr. Reddy's Laboratories Limited METHOD FOR IMPROVING THE STABILITY OF AN ANTIBODY FORMULATION
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025133872A1 (en) * 2023-12-19 2025-06-26 Intas Pharmaceuticals Ltd. Method for reducing oxidation levels in vedolizumab during cell culture process
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
US20260016226A1 (en) * 2024-07-14 2026-01-15 Frei Jonathan Advanced lyophilization control interfaces and techniques
US20260015407A1 (en) 2024-07-15 2026-01-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3852236T2 (de) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Verfahren zur Kontrolle der Leukozyten-Extravasation.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
HK1007683A1 (en) 1992-02-12 1999-04-23 Biogen, Inc. Treatment for inflammatory bowel disease
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995019790A1 (en) 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP1485127B1 (en) * 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
NZ536504A (en) 2002-05-24 2008-04-30 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
DE60314175T2 (de) 2002-11-18 2008-01-24 Chemocentryx Inc., Mountain View Arylsulfonamide
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
KR101364276B1 (ko) * 2004-09-03 2014-02-20 제넨테크, 인크. 인간화 항-베타７ 길항제 및 그의 용도
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
SG183709A1 (en) * 2007-08-08 2012-09-27 Abbott Lab Compositions and methods for crystallizing antibodies
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
RU2595836C2 (ru) 2011-03-31 2016-08-27 Дженентек, Инк. Способы введения антагонистов интегрина бета7
EP3311834A1 (en) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
EP3468597A1 (en) * 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease

Also Published As

Publication number Publication date
US20250041424A1 (en) 2025-02-06
CN108129565A (zh) 2018-06-08
MX356827B (es) 2018-06-15
CA3028209C (en) 2021-01-05
ZA201308069B (en) 2016-01-27
CL2017000830A1 (es) 2017-12-22
EP3329965B1 (en) 2025-03-19
MX348814B (es) 2017-06-30
AU2016231469B2 (en) 2018-12-20
US20250288679A1 (en) 2025-09-18
NZ617833A (en) 2016-04-29
ES3016382T3 (en) 2025-05-09
JP2023076616A (ja) 2023-06-01
US9764033B2 (en) 2017-09-19
MX2021006723A (es) 2022-05-03
MY172735A (en) 2019-12-11
KR20180050435A (ko) 2018-05-14
ME02859B (me) 2018-04-20
KR102096484B1 (ko) 2020-04-02
JP2024098027A (ja) 2024-07-19
IL296847A (en) 2022-11-01
HUE036663T2 (hu) 2018-07-30
AU2018278866B2 (en) 2020-07-09
AU2022231726A1 (en) 2022-10-06
FI3329965T3 (fi) 2025-04-30
JP2019108400A (ja) 2019-07-04
KR20170116217A (ko) 2017-10-18
US20140377251A1 (en) 2014-12-25
AR086237A1 (es) 2013-11-27
JP6190360B2 (ja) 2017-08-30
LT2704798T (lt) 2017-10-25
AU2020250249B2 (en) 2022-10-06
SMT202500218T1 (it) 2025-07-22
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
PL2704798T3 (pl) 2017-12-29
KR101923371B1 (ko) 2018-11-29
US20220370617A1 (en) 2022-11-24
CN108079291A (zh) 2018-05-29
KR20250094743A (ko) 2025-06-25
TWI556828B (zh) 2016-11-11
EP3329965A1 (en) 2018-06-06
SMT201700508T1 (it) 2017-11-15
JP2017137351A (ja) 2017-08-10
DK3329965T3 (da) 2025-04-07
SG194652A1 (en) 2013-12-30
AU2025202434A1 (en) 2025-04-24
US20190076532A1 (en) 2019-03-14
EP2704798A2 (en) 2014-03-12
US20120282249A1 (en) 2012-11-08
US12053526B2 (en) 2024-08-06
AU2012250873A1 (en) 2013-05-09
MX383317B (es) 2025-03-13
PH12018500030A1 (en) 2018-10-15
CO6801647A2 (es) 2013-11-29
US20250000981A1 (en) 2025-01-02
IL267668A (en) 2019-08-29
JP2018150388A (ja) 2018-09-27
CN108079291B (zh) 2022-04-08
TWI664980B (zh) 2019-07-11
KR102465394B1 (ko) 2022-11-09
US20170002078A1 (en) 2017-01-05
DK2704798T3 (en) 2017-10-23
US12171832B2 (en) 2024-12-24
US20160340432A1 (en) 2016-11-24
EP4378484A2 (en) 2024-06-05
KR20200035503A (ko) 2020-04-03
EA201391614A1 (ru) 2014-07-30
JP2021113223A (ja) 2021-08-05
IL296838A (en) 2022-11-01
DOP2013000253A (es) 2013-12-31
CA3028209A1 (en) 2012-11-08
CN103608071B (zh) 2017-12-26
EP2704798B1 (en) 2017-07-12
MA35136B1 (fr) 2014-05-02
IL267668B (en) 2020-10-29
RS56397B1 (sr) 2017-12-29
AU2019201926A1 (en) 2019-04-11
MY183471A (en) 2021-02-19
KR20210084711A (ko) 2021-07-07
UA126545C2 (uk) 2022-11-02
CY1119435T1 (el) 2018-03-07
WO2012151248A3 (en) 2013-02-28
AU2022231726B2 (en) 2025-01-09
EP3263178A1 (en) 2018-01-03
CA2834867A1 (en) 2012-11-08
JP7492057B2 (ja) 2024-05-28
ZA201707158B (en) 2019-01-30
US9663579B2 (en) 2017-05-30
JP6534415B2 (ja) 2019-06-26
IL275038B2 (en) 2023-03-01
IL275038B (en) 2022-11-01
AU2020250249A1 (en) 2020-11-05
PE20190405A1 (es) 2019-03-14
JP6878489B2 (ja) 2021-05-26
SI2704798T1 (sl) 2017-12-29
PL3329965T3 (pl) 2025-04-28
CN108129565B (zh) 2022-09-20
AU2018278866A1 (en) 2019-01-03
HRP20250472T1 (hr) 2025-06-06
TWI664978B (zh) 2019-07-11
AU2016231469A1 (en) 2016-10-06
ES2645187T3 (es) 2017-12-04
KR20180127540A (ko) 2018-11-28
US20180289811A1 (en) 2018-10-11
ZA201806946B (en) 2022-03-30
GEP201706734B (en) 2017-09-25
UA116189C2 (uk) 2018-02-26
HUE071510T2 (hu) 2025-09-28
PH12018500030B1 (en) 2022-05-04
EP4378484A3 (en) 2024-09-04
US20250295786A1 (en) 2025-09-25
IL229104A0 (en) 2013-12-31
EA032729B1 (ru) 2019-07-31
KR20140145953A (ko) 2014-12-24
AU2012250873B2 (en) 2016-07-07
HRP20171432T1 (hr) 2017-11-03
US10004808B2 (en) 2018-06-26
JP2014514346A (ja) 2014-06-19
TW201247223A (en) 2012-12-01
US20180207279A1 (en) 2018-07-26
CA2834867C (en) 2019-02-12
JP7258941B2 (ja) 2023-04-17
US10143752B2 (en) 2018-12-04
US20190231878A1 (en) 2019-08-01
WO2012151248A2 (en) 2012-11-08
US20160340431A1 (en) 2016-11-24
US20200206353A1 (en) 2020-07-02
MX2013012724A (es) 2013-12-06
TW201906631A (zh) 2019-02-16
RS66809B1 (sr) 2025-06-30
TW201718012A (zh) 2017-06-01
BR112013028424A2 (pt) 2021-05-04
EP3329965A3 (en) 2018-12-12
PT3329965T (pt) 2025-04-02
CN108187042A (zh) 2018-06-22
KR102275603B1 (ko) 2021-07-08
PH12020500336A1 (en) 2021-02-22
ECSP22034515A (es) 2022-05-31
PE20141175A1 (es) 2014-09-25
IL275038A (en) 2020-07-30
PT2704798T (pt) 2017-11-14
PH12013502236A1 (en) 2014-01-06
JP6473845B2 (ja) 2019-02-20
UY34053A (es) 2012-11-30
LT3329965T (lt) 2025-06-10
CR20130677A (es) 2014-10-07
CN103608071A (zh) 2014-02-26
SI3329965T1 (sl) 2025-07-31
HK1256106A1 (en) 2019-09-13
US20210052733A1 (en) 2021-02-25
CL2013003146A1 (es) 2014-07-25
HK1249466A1 (en) 2018-11-02

Similar Documents

Publication Publication Date Title
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
ECSP22046340A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201400111A (es) Triazolopiridinas sustituidas
MX2013003365A (es) Composicion farmaceutica.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
ECSP14033371A (es) Composiciones farmacéuticas y tratamiento de mastitis
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112013008749A2 (pt) análogos de ciclosporina
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
UY34031A (es) Componente de éster aromático en la formulación de composiciones agroquímicas
BR112016007031A8 (pt) composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
ECSP13013059A (es) Formulación para anticuerpo anti- 4 7
EA201990056A1 (ru) КОМПОЗИЦИЯ АНТИ-α4β7 АНТИТЕЛА
UA112984C2 (uk) КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА